DF6215, an α-optimized IL-2-Fc fusion, expands immune effectors and drives robust preclinical anti-tumor activity
Adam Stockmann(TScan Therapeutics (United States)), Ann Cheung(Wave Dragon (Denmark)), Ching-Shin Huang(Pfizer (United States)), Nicolai Wagtmann(Howard Hughes Medical Institute), Jingya Ma(Millennium Engineering and Integration (United States)), Sylvia Vincent(TScan Therapeutics (United States)), Daniel Fallon(Northeastern University), Danielle Talbot(TScan Therapeutics (United States)), Eva Gutierrez(TScan Therapeutics (United States)), Stuart W. Hicks(TScan Therapeutics (United States)), Lauren Herschelman(TScan Therapeutics (United States)), Patrick Kirby(TScan Therapeutics (United States))
Cited by 0
Related Papers
Substrate-Assisted Inhibition of Ubiquitin-like Protein-Activating Enzymes: The NEDD8 E1 Inhibitor MLN4924 Forms a NEDD8-AMP Mimetic In Situ
|Molecular Cell|2010|461
Structure of the inhibitory receptor for human natural killer cells resembles haematopoietic receptors
|Nature|1997|165
Cryo-EM structures of NPC1L1 reveal mechanisms of cholesterol transport and ezetimibe inhibition
|Science Advances|2020|95
A Novel Six-Rhodopsin System in a Single Archaeon
|Journal of Bacteriology|2010|54